549 research outputs found
Geometric optics and boundary layers for Nonlinear Schrodinger equations
We justify supercritical geometric optics in small time for the defocusing
semiclassical Nonlinear Schrodinger Equation for a large class of
non-necessarily homogeneous nonlinearities. The case of a half-space with
Neumann boundary condition is also studied.Comment: 44 page
Traveling waves for nonlinear Schr\"odinger equations with nonzero conditions at infinity, II
We prove the existence of nontrivial finite energy traveling waves for a
large class of nonlinear Schr\"odinger equations with nonzero conditions at
infinity (includindg the Gross-Pitaevskii and the so-called "cubic-quintic"
equations) in space dimension . We show that minimization of the
energy at fixed momentum can be used whenever the associated nonlinear
potential is nonnegative and it gives a set of orbitally stable traveling
waves, while minimization of the action at constant kinetic energy can be used
in all cases. We also explore the relationship between the families of
traveling waves obtained by different methods and we prove a sharp nonexistence
result for traveling waves with small energy.Comment: Final version, accepted for publication in the {\it Archive for
Rational Mechanics and Analysis.} The final publication is available at
Springer via http://dx.doi.org/10.1007/s00205-017-1131-
Convergence of Ginzburg-Landau functionals in 3-d superconductivity
In this paper we consider the asymptotic behavior of the Ginzburg- Landau
model for superconductivity in 3-d, in various energy regimes. We rigorously
derive, through an analysis via {\Gamma}-convergence, a reduced model for the
vortex density, and we deduce a curvature equation for the vortex lines. In a
companion paper, we describe further applications to superconductivity and
superfluidity, such as general expressions for the first critical magnetic
field H_{c1}, and the critical angular velocity of rotating Bose-Einstein
condensates.Comment: 45 page
Successful private–public funding of paediatric medicines research: lessons from the EU programme to fund research into off-patent medicines
The European Paediatric Regulation mandated the European Commission to fund research on off-patent medicines with demonstrated therapeutic interest for children. Responding to this mandate, five FP7 project calls were launched and 20 projects were granted. This paper aims to detail the funded projects and their preliminary results. Publicly
available sources have been consulted and a descriptive
analysis has been performed. Twenty Research Consortia
including 246 partners in 29 European and non-European
countries were created (involving 129 universities or public funded research organisations, 51 private companies with 40 SMEs, 7 patient associations). The funded projects investigate 24 medicines, covering 10 therapeutic areas in all paediatric age groups. In response to the Paediatric Regulation and to apply for a Paediatric Use Marketing Authorisation, 15 Paediatric Investigation Plans have been granted by the EMAPaediatric Committee, including 71 studies of whom 29 paediatric clinical trials, leading to a total of 7,300 children to be recruited in more than 380 investigational centres.
Conclusion: Notwithstanding the EU contribution for each
study is lower than similar publicly funded projects, and also considering the complexity of paediatric research, these projects are performing high-quality research and are progressing towards the increase of new paediatric medicines on the market. Private–public partnerships have been effectively implemented, providing a good example for future collaborative actions. Since these projects cover a limited number of offpatent drugs and many unmet therapeutic needs in paediatrics remain, it is crucial foreseeing new similar initiatives in forthcoming European funding programmes
PP270—Computational modeling of dravet syndrome
e102 Volume 35 Number 8S clorazepate (20mg 2× /d), and pregabalin (100 mg 3× /d). Because of resurgence of severe anxio-depressive symptoms, without any change of the treatment, the patient was readmitted 2 months later. Despite increasing the dose of clomipramine up to 225 mg/d, there was no clinical improvement, and the patient finally attempted to her life by abusing drugs. She then improved after 2 weeks on clomipramine IV (50 mg/d). Compliance was estimated good and no pharmacokinetic interactions with the rest of the treatment were found. C and DC plasma levels were measured, and CYP2D6/CYP2C19 genotype analyzed. Results: The plasma levels of C and DC are given in the Table below. Measures were done at the steady state and at trough concentration for IV treatment and 10 hours after the last dose for oral treatment
Travelling waves for the Gross-Pitaevskii equation II
The purpose of this paper is to provide a rigorous mathematical proof of the
existence of travelling wave solutions to the Gross-Pitaevskii equation in
dimensions two and three. Our arguments, based on minimization under
constraints, yield a full branch of solutions, and extend earlier results,
where only a part of the branch was built. In dimension three, we also show
that there are no travelling wave solutions of small energy.Comment: Final version accepted for publication in Communications in
Mathematical Physics with a few minor corrections and added remark
Groupwise Multimodal Image Registration using Joint Total Variation
In medical imaging it is common practice to acquire a wide range of
modalities (MRI, CT, PET, etc.), to highlight different structures or
pathologies. As patient movement between scans or scanning session is
unavoidable, registration is often an essential step before any subsequent
image analysis. In this paper, we introduce a cost function based on joint
total variation for such multimodal image registration. This cost function has
the advantage of enabling principled, groupwise alignment of multiple images,
whilst being insensitive to strong intensity non-uniformities. We evaluate our
algorithm on rigidly aligning both simulated and real 3D brain scans. This
validation shows robustness to strong intensity non-uniformities and low
registration errors for CT/PET to MRI alignment. Our implementation is publicly
available at https://github.com/brudfors/coregistration-njtv
An innovative ethosuximide granule formulation designed for pediatric use: Comparative pharmacokinetics, safety, tolerability, and palatability profile versus reference syrup.
Ethosuximide, the first-line therapy for childhood absence epilepsy, is currently formulated as a syrup (Zarontin®, Pfizer) with a bitter taste and high sugar content, poorly adapted to children, and a ketogenic diet. The collaborative European FP7 project KIEKIDS aimed at developing an innovative sugar-free, tasteless formulation convenient for pediatric use. This dual Phase-I study evaluated two granule formulations based on lipid multiparticulate (LMP) technology. Two panels of 6 healthy adult volunteers underwent a randomized, placebo-controlled, partly blinded, 3-way cross-over trial, comparing ethosuximide granules A or B with placebo granules and syrup at single 10 mg/kg doses. Corresponding plasma pharmacokinetic profiles of ethosuximide were compared, along with palatability, safety, and tolerability. The LMP granule A proved suboptimal due to bitterness and adherence to beaker walls, while the optimized granule B revealed excellent palatability, similar to placebo granules, and low adherence to glass. The relative bioavailability of granules A versus syrup, based on dose-normalized C <sub>max</sub> and AUC <sub>0-∞</sub> was 93.7% [90% CI: 76.3-115.1] and 96.1% [91.0-101.5], respectively. For granules B it was 87.6% [81.6-94.0] and 92.5% [88.5-96.6], respectively, with slightly delayed t <sub>max</sub> of 0.75 h [0.5-4.05] compared to syrup 0.5 h [0.3-0.8]. Tolerability visual analog scales revealed a trend for statistically non-significant improvement versus syrup at peak (30 min) for transient dizziness (both granules), fatigue (granules A), and anxiety (granules B). The innovative ethosuximide granule formulation B achieves a suitable profile for pediatric use, being sugar-free, tasteless, bioequivalent, and well-tolerated while enabling precise adjustment to body weight
Asymmetric Hypsarrhythmia: Clinical Electroencephalographic and Radiological Findings
Twenty-six children (16 boys and 10 girls) with hypsarrhythmia and infantile spasms (IS) were studied at the University of Michigan EEG Laboratory in a 4-year period. Six (2 boys, 4 girls), had asymmetric hypsarrhythmia with a preponderance of both slowing and epileptic form activity over one hemisphere. All 6 had the symptomatic form of IS, 4 with dysplastic conditions, 1 with porencephaly from a cerebral infarct, and 1 with hypoxic-ischemic encephalopathy. Five children had focal abnormalities on either physical examination or imaging studies. Four had the highest amplitude slowing and most epileptiform activity ipsilateral to the lesion, in 1, it was contralateral. Asymmetric hypsarrhythmia constituted 23% of cases with hypsarrhythmia examined at our EEG laboratory. The significant success in surgical therapy for some children with IS indicates the importance of identifying focal hemispheric abnormalities even if they are not apparent clinically. EEG may suggest focal changes not detected clinically or radiologically.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/66439/1/j.1528-1157.1995.tb01663.x.pd
- …